ジルビスクの市場規模、シェア、動向分析レポート：適応症別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

ジルビスク（ジルコプラン）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、ジルビスク（ジルコプラン）の世界市場規模は2030年までに6億7,958万米ドルに達すると予測され、予測期間中に28.39%のCAGRで拡大する見込みです。

UCB社が開発したファーストインクラスの自己投与型皮下補体C5阻害剤ジルビスク（Zilbrysq）は、全身型重症筋無力症（gMG）の治療パラダイムを急速に再定義しつつあります。米国、EU、日本、カナダ、韓国で承認されたこの治療薬は、そのユニークな投与モデルと標的メカニズムにより、稀な自己免疫性神経筋疾患領域において価値の高い治療薬として位置づけられています。

特に、副腎皮質ステロイド、IVIg、血漿交換による管理が不十分な重症筋無力症（gMG）患者を対象として、メカニズムに基づく標的治療の優先順位が高まっていることが重要な推進力となっています。ジルビスクの終末補体活性化を選択的に阻害する能力は、臨床医に免疫学的特異性と長期的安全性を重視した最新の治療アルゴリズムに沿った高精度の介入を提供します。さらに、1日1回皮下投与という製剤は、従来の病院依存モデルを破壊し、治療の分散化を可能にし、外来や在宅での長期的な疾患コントロールをサポートします。このことは、患者のアドヒアランスを向上させるだけでなく、支払者にとってますます重要な考慮事項となっている輸液関連コストの削減にもつながっています。SC C5には直接的な競合品がないため、その商業的位置づけはさらに高まっています。さらに、希少疾病治療薬の優遇措置、迅速な承認、主要市場における償還の優先順位付けなどの希少疾病政策の枠組みが、アクセスや処方者の取り込みを加速させています。このようなダイナミクスは、予測可能な治療集団や治療の重複の少なさと相まって、MG治療の状況におけるジルビスクの戦略的価値を引き続き強化しています。

ジルコプランは、補体成分5（C5）の切断を選択的に阻害することで、AChR抗体陽性gMGにおける神経筋接合部障害で中心的な役割を果たす膜攻撃複合体（C5b-9）の形成を阻害します。従来の免疫抑制剤や生物学的製剤の静脈内投与とは異なり、ジルビスクの投与は1日1回の皮下注射であるため、患者は自宅で治療を自己管理することができます。これにより、治療負担が大幅に軽減され、特に病院での点滴治療から移行する患者の長期アドヒアランスが向上します。

2024年現在、ジルビスクはgMGの適応症シェアを100％有しており、PNH、ALS、IMNMの臨床プログラムが戦略的に中止されたため、追加適応症の積極的な開発は行われていないです。しかし、その強力な有効性プロファイル、簡便なSCデリバリー、2030年までの希少疾病用医薬品としての独占権により、承認された母集団において大きな商業的堀と持続的な収益の可能性があります。

患者教育、アドヒアランス・モニタリング、コールドチェーン・ロジスティクスの必要性を反映し、2024年には調剤量の70％以上を専門薬局が占める。病院薬局は、新規に診断された症例や複雑な症例の治療開始やサポートに引き続き役割を果たしています。一方、在宅ヘルスケアプロバイダーは、分散型ケアと在宅治療インフラの改善に対する需要の高まりにより、最も急成長している流通セグメントです。

2023年10月、米国FDAは、MG-ADLおよびQMGのスコアがプラセボに対して統計学的に有意に改善することを証明した重要なRAISE試験により、ジルビスクを承認しました。その後、欧州委員会が2023年12月に承認し、英国（2024年1月）、カナダ（2024年7月）、韓国（2024年11月）でも承認されました。さらに、2024年5月に発表された60週間の延長試験（RAISE-XT）により、本薬剤の長期安全性とgMGにおける臨床的有用性の持続性が検証されました。

さらに、2024年11月に発表されたヒューマンファクター検証試験では、ジルビスクのプレフィルドシリンジが患者、介護者、医療従事者にとって使いやすいことが確認され、在宅での適用可能性と患者中心のケアモデルとの整合性が強化されました。精密治療に対する需要が世界的に高まる中、UCBはアジア太平洋、ラテンアメリカ、中東での市場拡大に投資しています。サプライチェーンの拡張性、実臨床データの作成、デジタルアドヒアランスプラットフォームに戦略的に重点を置くことで、世界な展開とケアの継続性を強化することが期待されます。

ジルビスクの商業的成功は、病院での投与を必要とせず、持続的な疾患コントロールを提供する自己投与型のメカニズム特異的生物製剤への業界全体のシフトを反映しています。ジルコプランは、強力な臨床的基盤を有し、SC補体阻害剤クラスでは直接競合が限られていることから、患者の転帰とQOLの有意義な改善を促進し、遺伝子組換え疾患の市場リーダーであり続ける態勢を整えています。

ジルビスク（ジルコプラン）市場レポートハイライト

• 全般性重症筋無力症（gMG）は、2024年においても市場の独占的かつ主要な適応症であり、市場シェアの100%を占める。抗アセチルコリン受容体（AChR）抗体陽性患者の高い有病率と、補体C5阻害剤としてのジルコプランの標的作用機序が相まって、強力な採用が進みました。良好な臨床試験結果、希少疾病用医薬品の独占的使用権、主要市場における最新の治療ガイドラインへの掲載により、特に従来の免疫抑制剤や点滴治療から移行する患者を中心に、導入が加速しています。
• 2024年の同市場における販売チャネル別シェアでは、専門薬局が70.35%を占め、最大でした。この優位性は、この薬剤が高コストの希少生物学的製剤に分類され、コールドチェーン物流、患者教育、長期的なアドヒアランスサポートを必要とすることに起因しています。専門薬局はまた、特にジルコプランのような自己投与療法において、リフィルの調整やベネフィットの確認を管理する上で重要な役割を果たしています。
• 北米は2024年のジルビスク市場を77.78％のシェアでリードしており、これは早期の承認、補体阻害薬に対する処方医の幅広い理解、およびgMGの高い診断率に支えられています。同地域では専門薬局のネットワークが確立しており、高額な希少疾病用医薬品に対する支払者の償還意欲が高いことも、好調な商業実績をさらに後押ししています。米国とカナダの臨床現場から得られた実際のエビデンスは、治療の継続性を強化し、処方者の裾野を広げることが期待されます。
• UCBは、戦略的な薬事申請、的を絞った医師教育、市販後データ作成への投資などに支えられ、世界市場をリードし続けています。同社の長期的な成長戦略は、サプライチェーンの拡張性、実臨床でのアドヒアランスのサポート、そして特に日本、カナダ、韓国などの市場における地域的な拡大を重視していることを裏付けています。UCBは補体介在性神経筋障害に特化したポジショニングをとっており、SCベースの代替品が限られている市場での競争力を強化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ジルビスク（ジルコプラン）市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
• パイプライン分析
• 特許満了分析
• 価格分析

第4章 ジルビスク（ジルコプラン）市場：適応症のビジネス分析

• 適応症市場シェア、2024年および2030年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 全身性重症筋無力症（gMG）
• その他

第5章 ジルビスク（ジルコプラン）市場：流通チャネルのビジネス分析

• 流通チャネル市場シェア、2024年および2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 専門薬局
• 病院/施設併設薬局
• 在宅ヘルスケア提供者

第6章 ジルビスク（ジルコプラン）市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • UCB

第8章 結論

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Zilbrysq (Zilucoplan) Market, by region, 2018 - 2030 (USD Million)
• Table 4 Global Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 5 Global Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 6 North America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
• Table 7 North America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 8 North America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 U.S Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 10 U.S Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 Canada Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 12 Canada Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Mexico Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 14 Mexico Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Europe Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 17 Europe Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 UK Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 19 UK Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 Germany Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 21 Germany Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 France Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 23 France Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 Italy Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 25 Italy Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Spain Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 27 Spain Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Norway Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 29 Norway Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 Denmark Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 31 Denmark Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Sweden Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 33 Sweden Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Japan Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 38 Japan Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 39 China Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 40 China Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 India Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 42 India Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Australia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 44 Australia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 45 South Korea Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 46 South Korea Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Thailand Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 48 Thailand Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Latin America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 51 Latin America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Brazil Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 53 Brazil Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 Argentina Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 55 Argentina Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 South Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 60 South Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 UAE Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 64 UAE Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Kuwait Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
• Table 66 Kuwait Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Zilbrysq (Zilucoplan) Market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Indication and Distribution Channel outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Zilbrysq (Zilucoplan) Market dynamics
• Fig. 12 Zilbrysq (Zilucoplan) Market: Porter's five forces analysis
• Fig. 13 Zilbrysq (Zilucoplan) Market: PESTLE analysis
• Fig. 14 Indication market, 2018 - 2030 (USD Million)
• Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
• Fig. 16 Others market, 2018 - 2030 (USD Million)
• Fig. 17 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 18 Specialty Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 19 Hospital/Institution-Based Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 20 Home Healthcare Providers market, 2018 - 2030 (USD Million)
• Fig. 21 Zilbrysq (Zilucoplan) Market revenue, by region
• Fig. 22 Regional marketplace: Key takeaways
• Fig. 23 North America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 24 U.S. country dynamics
• Fig. 25 U.S. Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 26 Canada country dynamics
• Fig. 27 Canada Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 28 Mexico country dynamics
• Fig. 29 Mexico Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 30 Europe Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 31 UK country dynamics
• Fig. 32 UK Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 33 Germany country dynamics
• Fig. 34 Germany Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 35 France country dynamics
• Fig. 36 France Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 37 Italy country dynamics
• Fig. 38 Italy Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 39 Spain country dynamics
• Fig. 40 Spain Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 41 Norway country dynamics
• Fig. 42 Norway Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 43 Sweden country dynamics
• Fig. 44 Sweden Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 45 Denmark country dynamics
• Fig. 46 Denmark Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 48 Japan country dynamics
• Fig. 49 Japan Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 50 China country dynamics
• Fig. 51 China Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 52 India country dynamics
• Fig. 53 India Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 54 Australia country dynamics
• Fig. 55 Australia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 56 South Korea country dynamics
• Fig. 57 South Korea Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 58 Thailand country dynamics
• Fig. 59 Thailand Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 60 Latin America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 61 Brazil country dynamics
• Fig. 62 Brazil Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 63 Argentina country dynamics
• Fig. 64 Argentina Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 65 MEA Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 66 South Africa country dynamics
• Fig. 67 South Africa Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 68 Saudi Arabia country dynamics
• Fig. 69 Saudi Arabia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 70 UAE country dynamics
• Fig. 71 UAE Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 72 Kuwait country dynamics
• Fig. 73 Kuwait Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
• Fig. 74 Company categorization
• Fig. 75 Company market position analysis
• Fig. 76 Strategic framework

Zilbrysq (Zilucoplan) Market Growth & Trends:

The global zilbrysq (zilucoplan) market size is anticipated to reach USD 679.58 million by 2030 and is expected to expand at a CAGR of 28.39% during the forecast period, according to a new report by Grand View Research, Inc. Zilbrysq, a first-in-class self-administered subcutaneous complement C5 inhibitor developed by UCB, is rapidly redefining the treatment paradigm for generalized myasthenia gravis (gMG). Approved in the U.S., EU, Japan, Canada, and South Korea, the therapy's unique delivery model and targeted mechanism have positioned it as a high-value therapeutic in the rare autoimmune neuromuscular segment.

A key driver is the growing prioritization of targeted, mechanism-based therapies in generalized myasthenia gravis (gMG), particularly for patients inadequately managed by corticosteroids, IVIg, or plasma exchange. Zilbrysq's ability to selectively inhibit terminal complement activation provides clinicians with a high-precision intervention that aligns with modern treatment algorithms focused on immunological specificity and long-term safety. In addition, its once-daily subcutaneous formulation disrupts the traditional hospital-dependent model, enabling therapy decentralization and supporting long-term disease control in outpatient and home settings. This has not only improved patient adherence but also reduced infusion-related costs-an increasingly important consideration for payers. The absence of direct SC C5 competitors further enhances its commercial positioning. Moreover, rare disease policy frameworks, including orphan drug incentives, expedited approvals, and national reimbursement prioritization in key markets, have accelerated both access and prescriber uptake. These dynamics, combined with a predictable treatment population and low therapeutic redundancy, continue to reinforce Zilbrysq's strategic value within the gMG treatment landscape.

Zilucoplan works by selectively inhibiting the cleavage of complement component 5 (C5), preventing formation of the membrane attack complex (C5b-9), which plays a central role in neuromuscular junction damage in AChR antibody-positive gMG. Unlike traditional immunosuppressants or IV biologics, Zilbrysq is administered via once-daily subcutaneous injection, allowing patients to self-manage their therapy at home. This significantly reduces treatment burden and improves long-term adherence, particularly among patients transitioning away from hospital-based IV infusions.

As of 2024, Zilbrysq holds 100% indication share for gMG, with no active development in additional indications following the strategic discontinuation of clinical programs in PNH, ALS, and IMNM. However, its strong efficacy profile, convenient SC delivery, and orphan drug exclusivity until 2030 provide a significant commercial moat and sustained revenue potential in its approved population.

Specialty pharmacies serve as the primary distribution channel, accounting for over 70% of dispensed volumes in 2024, reflecting the need for coordinated patient education, adherence monitoring, and cold-chain logistics. Hospital pharmacies continue to play a role in treatment initiation and support for newly diagnosed or complex cases. Meanwhile, home healthcare providers represent the fastest-growing distribution segment, driven by increasing demand for decentralized care and improved at-home treatment infrastructure.

In October 2023, the U.S. FDA approved Zilbrysq, supported by the pivotal RAISE study, which demonstrated statistically significant improvements in MG-ADL and QMG scores versus placebo. Subsequently, the European Commission approved the therapy in December 2023, followed by authorizations in the UK (January 2024), Canada (July 2024), and South Korea (November 2024). Moreover, a 60-week extension study (RAISE-XT) published in May 2024 validated the drug's long-term safety and durability of clinical benefit in gMG.

Further bolstering its real-world readiness, a human factors validation study published in November 2024 confirmed the usability of Zilbrysq's prefilled syringe for patients, caregivers, and healthcare professionals, reinforcing its at-home applicability and alignment with patient-centric care models. As demand for precision therapies rises globally, UCB invests in market expansion across Asia Pacific, Latin America, and the Middle East. Strategic emphasis on supply chain scalability, real-world data generation, and digital adherence platforms is expected to enhance global reach and continuity of care.

The commercial success of Zilbrysq reflects a broader industry shift toward self-administered, mechanism-specific biologics that offer durable disease control without the need for hospital-based delivery. With a strong clinical foundation and limited direct competition in the SC complement inhibitor class, Zilucoplan is poised to remain a market leader in gMG, driving meaningful improvements in patient outcomes and quality of life.

Zilbrysq (Zilucoplan) Market Report Highlights:

• Generalized Myasthenia Gravis (gMG) remained the exclusive and leading indication in the market in 2024, accounting for 100% of the market share. The high prevalence of anti-acetylcholine receptor (AChR) antibody-positive patients, combined with Zilucoplan's targeted mechanism of action as a complement C5 inhibitor, has driven strong adoption. Favorable clinical trial outcomes, orphan drug exclusivity, and inclusion in updated treatment guidelines across key markets have accelerated uptake, particularly among patients transitioning from conventional immunosuppressants or IV therapies.
• Specialty Pharmacies held the largest share of the distribution channel segment in the market in 2024, accounting for 70.35% of dispensed volumes. This dominance is attributed to the drug's classification as a high-cost orphan biologic requiring cold-chain logistics, patient education, and long-term adherence support-all core competencies of specialty pharmacy providers. Specialty pharmacies also play a crucial role in managing refill coordination and benefit verification, especially for self-administered therapies like Zilucoplan.
• North America led the Zilbrysq market in 2024 with a share of 77.78%, supported by early regulatory approval, broad prescriber familiarity with complement inhibitors, and high diagnostic rates for gMG. The region's well-established specialty pharmacy networks and payer willingness to reimburse high-cost orphan drugs further support strong commercial performance. Real-world evidence from U.S. and Canadian clinical practice is expected to reinforce treatment persistence and expand the prescriber base.
• UCB continues to lead the global market, backed by strategic regulatory filings, targeted physician education, and investments in post-marketing data generation. The company's long-term growth strategy underpins its emphasis on supply chain scalability, real-world adherence support, and regional expansion, especially in markets like Japan, Canada, and South Korea. UCB's focused positioning within complement-mediated neuromuscular disorders strengthens its competitive advantage in a market with limited direct SC-based alternatives.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Zilbrysq (Zilucoplan) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
• 3.4. Pipeline Analysis
• 3.5. Patent Expiry Analysis
• 3.6. Pricing Analysis

Chapter 4. Zilbrysq (Zilucoplan) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Generalized Myasthenia Gravis (gMG)
  • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Zilbrysq (Zilucoplan) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Specialty Pharmacies
  • 5.4.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
• 5.5. Hospital/Institution-Based Pharmacies
  • 5.5.1. Hospital/Institution-Based Pharmacies Market, 2018 - 2030 (USD Million)
• 5.6. Home Healthcare Providers
  • 5.6.1. Home Healthcare Providers Market, 2018 - 2030 (USD Million)

Chapter 6. Zilbrysq (Zilucoplan) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. UCB
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion